Jun 24 2013
Research and Markets has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing" report to their offering.
This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for infectious disease. In the current medical diagnostics market, molecular diagnostics for infectious disease testing offers one of the brightest areas for growth and innovation.
The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of infectious disease.
Continuing new advancements in the ability to detect and diagnose infectious diseases are being made. Whereas before, detection and identification of many clinically important infectious agents was slow and expensive, and relied upon traditional culturing methods, and where there once were limited solutions offered by diagnostics, researchers and diagnostic companies are now at the cusp of overcoming such limitations by the use of nucleic acid mediated molecular diagnostics testing.
This market report analyzes the size and growth of the molecular diagnostics market in its applications for infectious disease detection and therapy, examining the factors that influence the various market segments and the dollar volume of sales, both in the U.S. and worldwide. The infectious disease market has been divided into the following parts for examination:
- Hepatitis infectious B and C disease
- Human immunodeficiency virus (HIV)
- Human papillomavirus (HPV)
- Influenza infectious disease
- Tuberculosis
- Sexually transmitted diseases (STDs)
- Chlamydia and gonorrhea blood screening
- Methicillin-resistant Staphylococcus aureus(MRSA)
- Vancomycin-resistant enterococci (VRE)
- Other infectious disease molecular diagnostic
Key Topics Covered:
1. Overview
2. Introduction to Molecular Diagnostics for Infectious Disease Testing
3. Infectious Disease Diagnostics Molecular Testing Market
4. Molecular Diagnostic Testing Technology for Infectious Disease Testing
5. Business
6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease
7. Regulatory Requirements
8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing
9. Economics of Anti-microbial Drug Resistance: The Persistent need for Anti-bacterials
10. Company Profiles
Companies Mentioned
- Abbott Laboratories
- AdvanDx
- Arcxis Biotechnologies
- Atlas Genetics
- AutoGenomics, Inc
- Becton, Dickinson and Company
- BioGenex Laboratories, Inc
- BioHelix Corporation
- bioMérieux
- Biocartis
- bioTheranostics
- Celera
- Cepheid
- EraGen Biosciences
- Exiqon A/S
- Genera Biosystems
- GenMark Diagnostics, Inc
- Genomix Biotech
- Gen-Probe
- PANTHER System
- Gene Express
- Genomica
- Great Basin Scientific
- Hologic
- Illumina, Inc
- Innogenetics NV
- Life Technologies
- Mobidiag
- Myconostica
- Nanosphere
- NorDiag ASA
- Qiagen NV
- Roche Ltd
- Seegene
- SIRS-Lab
- Source MDx
- TrimGen
- TrovaGene
- Veredus Laboratories
- Veridex
For more information visit http://www.researchandmarkets.com/research/zzk5p4/molecular
Source: http://www.researchandmarkets.com/